• Subscribe
  • About us
  • Advertise with us

NeuroSens

Menu

Skip to content
  • Home
  • Neurology
  • Psychiatry

Topic: MS

Daclizumab: DECIDE trial update

October 8, 2015  

Sequencing MS therapies: 2 studies

August 19, 2015  

Does psoriasis improve MS outcomes?

August 19, 2015  

Natalizumab in progressive MS: Phase II results

July 8, 2015  

ACTH revisited: melanocortins and MS

June 11, 2015  

Use of high-efficacy agents in MS: Updated data from AAN 2015

June 3, 2015  

Efficacy and effectiveness of first-line oral medications in MS

May 21, 2015  

Optimizing patient assessment in MS: NEDA and beyond

March 12, 2015  

NEUROSOUND: CHARCOT 2014 HIGHLIGHTS

February 11, 2015  

Pharma sales projected to top $1 trillion

February 4, 2015  
Previous
30
31
32
33
34
Next

Browse by Topic

  • MS (442)
  • EAN 2026 (2)
  • CLINICAL CASES (21)
  • AAN 2026 (3)
  • ACTRIMS Forum 2026 (4)
  • EPILEPSY (38)
  • AES 2025 (1)
  • BIOMARKERS IN MS (61)
  • ECTRIMS 2025 (7)
  • Library (18)
  • EAN 2025 (2)
  • AAN 2025 (5)
  • ACTRIMS 2025 (6)
  • AES 2024 (1)
  • ECTRIMS 2024 (6)
  • EAN 2024 (3)
  • AD (85)
  • AAN 2024 (5)
  • ACTRIMS Forum 2024 (2)
  • PD (77)
  • COVID-19 (58)
  • MIGRAINE (25)
  • DEPRESSION (36)
  • STROKE (22)
  • SCHIZOPHRENIA (25)
  • DEMENTIA (10)
  • SLEEP (2)
  • PAIN (3)
  • BPD (4)
  • ALS (1)

Popular Posts

  • Proton pump inhibitors linked to neurological conditions posted on November 29, 2019
  • Anti-CD20 therapy in MS: comparing efficacy and safety posted on July 21, 2026
  • Management of refractory epilepsy: highlights from ILAE 2025 posted on October 29, 2025
Copyright 2026 Lind Publishing Inc All rights reserved. Developed by Integration New Media, INC. (INM)
Contact Us Terms and Conditions